Outcome of pulmonary multidrug-resistant tuberculosis: A 6-yr follow-up study

C. Y. Chiang, D. A. Enarson, M. C. Yu, K. J. Bai, R. M. Huang, C. J. Hsu, J. Suo, T. P. Lin

Research output: Contribution to journalArticlepeer-review

106 Citations (Scopus)


A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (Cl) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% Cl 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis.

Original languageEnglish
Pages (from-to)980-985
Number of pages6
JournalEuropean Respiratory Journal
Issue number5
Publication statusPublished - Nov 2006
Externally publishedYes


  • Death
  • Follow-up
  • Multidrug resistant
  • Relapse
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Outcome of pulmonary multidrug-resistant tuberculosis: A 6-yr follow-up study'. Together they form a unique fingerprint.

Cite this